Leap Therapeutics, Inc. (LPTX): Price and Financial Metrics
LPTX Price/Volume Stats
| Current price | $3.18 | 52-week high | $10.20 |
| Prev. close | $3.29 | 52-week low | $1.24 |
| Day low | $3.11 | Volume | 99,868 |
| Day high | $3.29 | Avg. volume | 314,375 |
| 50-day MA | $2.77 | Dividend yield | N/A |
| 200-day MA | $2.51 | Market Cap | 81.41M |
LPTX Stock Price Chart Interactive Chart >
Leap Therapeutics, Inc. (LPTX) Company Bio
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in acquiring and developing therapeutics in cancer biology. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Latest LPTX News From Around the Web
Below are the latest news stories about LEAP THERAPEUTICS INC that investors may wish to consider to help them evaluate LPTX as an investment opportunity.
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer |
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York, NY. |
Leap Therapeutics Reports Third Quarter 2023 Financial ResultsLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023. |
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ... |
These 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says BairdIn the classic tune by Kenny Rogers, ‘The Gambler,’ he sang, ‘Every hand’s a winner and every hand’s a loser…’ These words hold valuable wisdom that should resonate with every investor. Regardless of your chosen investment strategy, achieving success in the stock market ultimately hinges on mastering the art of balancing risk and reward. Few segments of the stock market offer a higher potential return for the risk involved than the penny stocks, those equities priced at $5 or less. These are sto |
LPTX Price Returns
| 1-mo | 28.23% |
| 3-mo | 30.33% |
| 6-mo | 127.14% |
| 1-year | -12.37% |
| 3-year | -81.83% |
| 5-year | -81.29% |
| YTD | -23.28% |
| 2023 | -7.89% |
| 2022 | -86.11% |
| 2021 | 44.00% |
| 2020 | 100.89% |
| 2019 | -44.00% |
Loading social stream, please wait...